Marrow-ablative chemotherapy and re-irradiation are associated with improved overall survival in patients with relapsed central nervous system nongerminomatous germ cell tumors. Journal of Neuro-Oncology. 2026; 177(3).
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. Transplantation and Cellular Therapy. 2026.
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel. Blood advances. 2026; 10(1):106-110.
Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations. Neuro-Oncology. 2026; 28(4):847-863.
Long-term Ocular Safety in Children Treated with Mitogen-Activated Protein Kinase Pathway Inhibitor Therapy. Ophthalmology (Rochester, Minn.). 2026; 133(2):291-294.
Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell Reports Medicine. 2026; 7(5):102782.
Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study. Journal of Clinical Oncology. 2026; 44(16_suppl):11518-11518.
CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose. Pediatric Blood and Cancer. 2026; 73(6):e70268.
Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception. Journal of the National Cancer Institute. 2026.
P-522. Epidemiology of respiratory viral infections in pediatric acute leukemia patients. Open Forum Infectious Diseases. 2026; 13(Supplement_1):ofaf695.737.
Wide Ranging Neurobehavioral Phenotype in Individuals With Costello Syndrome. American Journal of Medical Genetics, Part A. 2026; 200(5):1138-1144.
FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases. Radiotherapy and Oncology. 2026; 111671.
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Transplantation and Cellular Therapy. 2026.
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. Blood advances. 2026; 10(1):70-74.
DNMT3A R882C variant in a patient with a presumed pineal gland tumor, highlighting potential tumor susceptibility in Tatton-Brown-Rahman syndrome. Cancer Genetics. 2026; 302-303:162-165.
Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia. JCI Insight. 2026; 11(4).
Biomarker Elevations Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome after CD19-Directed CAR-T Therapy in Children and Young Adults with Acute B-Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 2026; 32(2):s177.
DEK Loss Induces Task-specific Deficits in Learning and Memory and Reprograms the Hippocampal Transcriptome in Mice. Molecular Neurobiology. 2026; 63(1).
MEK inhibitor-induced dropped head syndrome in pediatrics. Neuro-Oncology Pediatrics. 2026; 2(2):wuag024.
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study. The Lancet Haematology. 2026; 13(3):e144-e156.
Outcomes of Allogeneic Stem Cell Transplantation In the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia Based on Transplant Center: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Transplantation and Cellular Therapy. 2026; 32(2):s112.
Base-Edited Breakthrough: Universal CD7 Chimeric Antigen Receptor T Cells Rewriting the Playbook for Relapsed T-Cell Acute Lymphoblastic Leukemia. The Hematologist. 2026; 23(3).
Discrepancies between primary and secondary interpretations of pediatric nuclear medicine imaging examinations. Pediatric Radiology. 2026; 56(2):464-472.
LONG-TERM CRYOPRESERVATION PRESERVES THE BIOLOGICAL AND MECHANOBIOLOGICAL ACTIVITY OF THIRD-PARTY VIRUS-SPECIFIC T CELLS. Cytotherapy. 2026; 28(5):102608.
Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review. Surgical Neurology International. 2026; 17:252.
Multi-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas. Radiology: Artificial Intelligence. 2026; 8(3):e250902.
Patient-Level Barriers and Facilitators to Inpatient Physical Therapy in Adolescents and Young Adults With a Hematological Malignancy: A Qualitative Study. Pediatric Blood and Cancer. 2026; 73(4):e70129.
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment. Genetics in Medicine. 2026; 28(6):102561.
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST). Clinical Cancer Research. 2026; 32(6):1068-1077.
In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy. Clinical and Translational Radiation Oncology. 2026; 56:101046.
Pain, Internalizing Symptoms, Posttraumatic Stress, and Alcohol Use Among Young Adult Survivors of Cancer. Pediatric Blood and Cancer. 2026; 73(4):e70154.
ID #141 The Use of MEK Inhibitors for Neurofibromatosis Type 1-Associated High Grade Glioma and High-Grade Astrocytoma with Piloid Features in Children and Young Adults: A Real-World Cohort Analysis. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.032.
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma. Neuro-Oncology. 2026.
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. Neuro-Oncology Advances. 2026; 8(Suppl 2):ii14-ii24.
Clinical safety and efficacy of bevacizumab in combination with mitogen-activated protein kinase kinase inhibitor therapy for glioma: a retrospective analysis. Neuro-Oncology Pediatrics. 2026; 2(1).
ID #1015 A murine model system for IDH-mutant 1p/19q-codeleted oligodendroglioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.446.
ID #1132 CONNECT TarGeT-A molecularly-guided phase 2 trial for children and young adults newly diagnosed with high-grade glioma (HGG), including diffuse intrinsic pontine glioma (DIPG): (1) Ribociclib and everolimus for HGG/DIPG with cell cycle and/or PI3K/mTOR pathway alterations, and (2) Ribociclib and temozolomide for diffuse hemispheric glioma (DHG), H3G34-mutant. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.514.
ID #1122 Preliminary feasibility of an international, multidisciplinary central screening platform for the CONNECT TarGeT molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG) Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.507.
Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma. Neuro-Oncology. 2026; 28(2):535-551.
Maternal-Fetal Transmission of Diffuse Large B-Cell Lymphoma. Pediatric Blood and Cancer. 2026; 73(2):e32174.
Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. Journal of Clinical Oncology. 2026; 44(11):1003-1015.
A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy. Neuro-Oncology Practice. 2026; npag014.
Heart transplantation in pediatric oncology patients. JHLT Open. 2026; 12:100514.
Duration of Cryopreservation of Third-Party Viral Specific T-Cells (TP-VSTs) Does Not Influence Clinical Efficacy. Transplantation and Cellular Therapy. 2026; 32(2):s131.
Feasibility Trial of a Tailored Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer. Pediatric Blood and Cancer. 2026; 73(1):e32127.
Validation of a Pre-Infusion Prediction Model for IEC-HS in Children and Young Adults with B-Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 2026; 32(2):s580.
ID #890 Multi-institutional analysis of outcomes of pediatric patients with high-risk (HR) WNT-subtype medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.384.
ID #634 Case Series of the Use of Trihexyphenidyl for Tremors in Pediatric Brain Tumors. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.247.
ID #472 Burnout Among Advanced Practice Providers in a Pediatric Oncology Setting. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.168.
ID #1002 Hematologic Toxicity during Proton Radiation: a Review of Weekly CBC Results at a Single Center. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.440.
Small Patients, Big Questions: Contemporary Therapeutic Strategies in Infants With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. The Hematologist. 2026; 23(4).
Diagnostic pitfall: BCOR immunoreactivity in a molecularly confirmed astroblastoma, MN1-altered (HGNET-MN1). Clinical Neuropathology. 2026; 45(1):32-35.
Group 4 Medulloblastomas of Early Childhood Treated With High-Dose Chemotherapy- and Craniospinal Irradiation-Sparing Approach. Pediatric Blood and Cancer. 2026; 73(5):e70181.
All hands on DEK: structural insights into a unique histone modifier and chromatin remodeler. Epigenetics and Chromatin. 2026; 19(1).
First, Do No Transplant? Emerging Evidence for Watchful Waiting in Select Juvenile Myelomonocytic Leukemia Patients. The Hematologist. 2026; 23(2).
No Data Zone Hope on Hold: Novel Drug Access Out of Reach for Children With Acute Myeloid Leukemia Despite Adult Successes. The Hematologist. 2026; 23(1).
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report. Transplantation and Cellular Therapy. 2026; 32(5):580.e1-580.e18.
An analysis of PD1 pathway activity in malignant pediatric central nervous system tumors: a pediatric brain tumor consortium study, PBTC-N13. Neuro-Oncology Pediatrics. 2026; 2(2):wuag020.
ID #476 Increased Prevalence of Optic Nerve Hypoplasia in Neurofibromatosis Type 1. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.170.
ID #18 CHD7-associated CHARGE Syndrome and a spinal schwannoma with a SH3PXD2A::HTRA1 fusion: A case report. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.001.
The first described report of a patient with CHD7-associated CHARGE syndrome and a spinal schwannoma with a SH3PXD2A::HTRA1 fusion; a case report and review of literature. Neuro-Oncology Pediatrics. 2026; 2(2):wuag034.
Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors. In: Handbook of Brain Tumor Chemotherapy Molecular Therapeutics and Immunotherapy. 2026:501-513.
Chapter 29 Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors. In: Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Elsevier; 2026:501-513.
ID #1028 A Retrospective Review Characterizing the Toxicities, Outcomes, and Molecular Characteristics of Adolescent and Young Adult Patients with Medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.457.
Abstract 2548: Circulating proteomic signatures for subtyping NF1 associated peripheral nerve sheath tumors. Cancer Research. 2026; 86(7_Supplement):2548-2548.
ID #854 Updated findings from a phase 1 study of savolitinib in recurrent, progressive, or refractory medulloblastoma (MB), high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), and central nervous system (CNS) tumors harboring MET aberrations: A Pediatric Brain Tumor Consortium Trial: PBTC-049. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.360.
ID #651 A phase 1/2 and surgical Pediatric Brain Tumor Consortium (PBTC) study evaluating the casein kinase 2 (CK2) inhibitor CX-4945 (silmitasertib sodium) in children and adults with recurrent sonic hedgehog (SHH) medulloblastoma (MB): PBTC-053. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.260.
The potential and risks of FLASH radiotherapy in pediatric patients. Neuro-Oncology Pediatrics. 2026; 2(1):wuaf014.
Parallels in Canonical Developmental Signaling Pathways between Normal Development and the Tumor Microenvironment. Cold Spring Harbor Perspectives in Medicine. 2026; 16(7).
Phase II One Arm Multicenter Study of Early Reinfusion of Tisagenlecleucel to Promote Durable B-cell Aplasia in Pediatric and Young Adult Patients with relapsed/refractory CD19-Positive B-cell Acute Lymphoblastic Leukemia (REFUEL) Transplantation and Cellular Therapy. 2026; 32(2):s593-s594.
ID #761 Feasibility study of hypofractionated radiotherapy in the setting of recurrent diffuse intrinsic pontine glioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.320.
Re-irradiation practices and outcomes in patients with diffuse intrinsic pontine glioma (DIPG): A report from the International DIPG/DMG Registry. Neuro-Oncology Pediatrics. 2026; 2(2):wuag013.
Lipid reprogramming of stratified squamous epithelium by the high-risk HPV E6 and E6/E7 oncoproteins. Metabolomics. 2026; 22(4).
ID #130 First Report of SHH-Activated Medulloblastoma in a Child With RRAS2-Related Noonan Syndrome. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.025.
Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell Chemical Biology. 2026; 33(1):59-73.e10.
Evolution of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Opportunities for Prevention and Therapeutic Strategies. Annual Review of Cancer Biology. 2026; 10(1):223-241.
Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children's Oncology Group study ACNS0331. Neuro-Oncology. 2026; 28(7):1772-1780.